Erectile Dysfunction Study

This is an interventional treatment trial for Erectile Dysfunction Read More

Inclusion Criteria:

1. Legal age (>18 years old)
2. An interval of at least 4-6 weeks between prior radical prostatectomy and study enrollment. Radical prostatectomy-induced ED is an immediate and progressive disorder as such interventions shortly following surgery may be the most effective at attenuating this disorder. It is expected that men who have undergone radical prostatectomy will be fully recovered at 4-6 weeks post surgery and will be receptive to an exercise intervention study at this time (capitalizing on the teachable moment). Additionally, the PI has demonstrated that maximal cardiopulmonary exercise testing is a safe, feasible, and acceptable assessment procedure 7±3 days post-craniotomy among 20 primary high grade primary brain tumor patients and 30±5 days post-pneumonectomy or lobectomy among 20 operable non-small cell lung cancer patients,
3. Karnofsky performance status of at least 70% at study entry,
4. Estimated life expectancy of ≥6 months,
5. Ability to read and understand English,
6. Primary attending urologist approval (Drs. Donatucci and Moul),
7. Signed informed consent prior to initiation of study-related procedures,
8. Willingness to be randomized,
9. Sedentary (i.e., men not performing regular exercise on at least 5 days a week, for at least 30 minutes each session, at a moderate or vigorous intensity for the past month). This definition is consistent with the national exercise recommendations guidelines and will ensure that only men not currently engaging in regular exercise (i.e., those who are the most likely to benefit) are recruited,
10. Postoperative erectile function (score ≤21 on the International Index of Erectile Function (IIEF) multidimensional questionnaire90). To avoid potential ceiling effects (i.e., testing of the intervention among men with only good erectile function), only men with an IIEF score ≤21, which indicates ED, will be recruited.

Exclusion Criteria:

1. Presence of a concurrent, actively treated other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer),
2. Presence of metastatic disease,
3. Scheduled to receive any form of adjuvant cancer therapy (i.e., radiation, chemotherapy, androgen deprivation therapy),

4. Subjects must not have any of following absolute contraindications to exercise testing as recommended by the American Thoracic Society91:

   • acute myocardial infarction (3-5 days)
   • unstable angina
   • uncontrolled arrhythmias causing symptoms or hemodynamic compromise
   • syncope
   • acute endocarditis
   • acute myocarditis or pericarditis
   • uncontrolled heart failure
   • acute pulmonary embolus or pulmonary infarction
   • thrombosis of lower extremities
   • suspected dissecting aneurysm
   • uncontrolled asthma
   • pulmonary edema
   • room air desaturation at rest ≤ 85%
   • respiratory failure
   • acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise
   • mental impairment leading to inability to cooperate.